Clinical trial
Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC)…
NCT00157196 · Merck KGaA, Darmstadt, Germany, Industry · Completed
Key facts
| NCT number | NCT00157196 |
|---|---|
| Title | Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease |
| Official title | A Multi-center, Non-randomized, Open Label Safety Study of BLP25 Liposome Vaccine (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Patients With Unresectable Stage III Disease |
| Lead sponsor | Merck KGaA, Darmstadt, Germany, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung, Lung Neoplasms |
| Intervention type | Biological, Drug, Other |
| Interventions | Tecemotide (L-BLP25), Single low dose cyclophosphamide, Best standard of care (BSC) |
| Enrollment | 22 |
| Start date | Apr 1, 2005 |
| Primary completion | Sep 1, 2007 |
| Completion | Apr 1, 2012 |
| First posted | Sep 12, 2005 |
| Last update posted | Aug 18, 2015 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: